When will the patents on ORABLOC expire, and when will generic ORABLOC be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466-001	Feb 26, 2010		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466-002	Feb 26, 2010		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: April 25, 2026

ORABLOC (Botulinum Toxin) Investment Scenario and Fundamentals Analysis

What is ORABLOC and where does it sit commercially?

ORABLOC is an oromucosal botulinum toxin formulation developed for local muscle overactivity, positioned in the broader botulinum neurotoxin category alongside established injectable products (e.g., onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA) and oral or oromucosal toxin delivery approaches. The key business distinction is route of administration: ORABLOC targets delivery through the oral mucosa rather than deep intramuscular injection.

Market positioning (conceptual)

Value driver vs injectables: lower administration friction (no needle-based office injection workflow).
Clinical burden vs oral small molecules: requires proving comparable botulinum potency, safety, and duration in the targeted indication(s) with reproducible oromucosal delivery.
Adoption friction: prescriber and reimbursement acceptance for a non-injectable botulinum platform.

Fundamental implication

ORABLOC’s investment case typically depends less on “patient convenience” narratives and more on (1) demonstrated duration and onset, (2) local safety profile and immunogenicity risk, and (3) payer and provider willingness to move away from established injection paradigms.

What are the core fundamentals that determine ORABLOC’s investability?

A botulinum toxin program’s fundamentals in investment terms map to development stage execution, competitive differentiation, and commercialization feasibility.

1) Clinical evidence strength

For ORABLOC, investors should underwrite the program only where there is clear documentation of:

Efficacy endpoint performance in its intended indication (standardized muscle activity measures or clinical scales).
Dose-response coherence (consistent improvement with dose changes and clear selection of a dosing regimen).
Duration (time to loss of effect) and onset (time to clinically meaningful effect).
Reproducibility across subjects and dosing sessions.

Business impact

If efficacy and duration are durable and dose-regimens are stable, ORABLOC can price and negotiate reimbursement with fewer clinical caveats.
If efficacy is inconsistent, the product becomes difficult to win formulary coverage against injected toxins and other therapies.

2) Safety and tolerability profile

Key fundamentals include:

Local tolerability (oral mucosa irritation, ulceration, swallowing discomfort, xerostomia).
Systemic exposure signals (weakness, dysphagia, distant spread-type concerns are still investor-relevant, even when administration is local to oral tissues).
Treatment-emergent adverse events frequency and severity across dosing levels.
Immunogenicity risk indicators (antibody formation and neutralizing antibody considerations are pivotal for toxin lifecycle economics).

Business impact

Safety that translates into fewer discontinuations and fewer contraindication restrictions supports broad market access.
Safety that creates new contraindication complexity can limit physician adoption and reimbursement.

3) Platform differentiation versus existing botulinum options

ORABLOC is competing against:

Injectables that already have established clinical guidelines and payer coverage.
Other non-injectable neurotoxin concepts if they reach market first.

Differentiation metrics that matter

Administration burden (training time, chair time, clinic throughput).
Patient setting (office, outpatient, or limited clinic-only).
Durability and retreatment interval.
Switchability (ability to move patients from injectable toxins based on response and tolerance).

4) Regulatory pathway feasibility

For a non-injectable toxin, regulatory success depends on:

Consistent manufacturing and delivery-system characterization (stability, content uniformity, and dose delivery to the target site).
Bioequivalence-style reasoning may not apply cleanly across toxin routes; regulators will expect robust bridging and dose selection logic.
Clear risk mitigation plans tied to oral exposure and local tissue effects.

How should investors model the ORABLOC revenue potential?

Revenue modeling for ORABLOC should start from how botulinum toxins typically monetize:

Indication breadth and line-of-therapy adoption.
Dose-frequency and average course cost.
Switch rates from injectables based on convenience plus comparable or superior clinical outcomes.

Investment-grade revenue logic

Assume a target indication with a definable treatment pathway.
Convert duration into retreatment frequency.
Use adoption curves tied to prescriber workflow fit (non-injectable convenience only converts if outcomes are comparable and safety is manageable).
Account for payer positioning: non-injectable toxins often face higher evidence thresholds to unlock formulary access.

Key sensitivity factors

Treatment interval (weeks per retreatment).
Real-world discontinuation rates due to local irritation or insufficient response.
Pricing power relative to injectables after evidence maturation.
Competitive entry timing (injectables and any other oral/oromucosal neurotoxin programs).

What does the competitive landscape imply for ORABLOC?

Botulinum toxin products are among the most intensively studied and reimbursed neurotherapeutics, which sets a high evidence bar.

Direct competition categories

Injected botulinum toxins in the same therapeutic area (if ORABLOC targets a condition treated with injected toxins).
Symptomatic alternatives (other neuromodulators, surgical or device-based interventions).
Emerging non-injectable neuromodulators (if relevant to the same patient population).

Competitive takeaway for investors

ORABLOC needs a “clinical plus workflow” advantage. If efficacy and duration do not match injectables, adoption depends on convenience alone, which is rarely sufficient at scale in established botulinum markets.

What are the key risks that can break the investment thesis?

For ORABLOC, the primary risk stack is standard for toxin delivery platforms but route-specific.

Scientific and clinical risks

Underperformance on duration or onset compared with expected benchmarks for the indication.
Local tolerability issues that limit repeat dosing or cause discontinuation.
Immunogenicity signals that shorten the effective lifecycle of patients or force regimen changes.

Regulatory and manufacturing risks

Delivery-system variability affecting dose delivery to target tissues.
Stability or manufacturability issues that delay scale-up or increase COGS and friction with quality systems.

Commercial risks

Formulary access lag relative to injectables.
Physician reluctance to switch toxin route without clear superior outcomes.
Price pressure if ORABLOC is perceived as a convenience-only substitute.

Investment scenario map: bull, base, bear

This is the risk-adjusted framing investors use to price toxin programs before major readouts.

Bull case

Clear efficacy and duration in the primary endpoint with manageable local adverse events.
Repeat dosing tolerability holds through multiple treatment cycles.
Regulatory approval supports broad labeling for the initial market segment.
Payer access accelerates due to evidence and a definable retreatment interval.

Base case

Efficacy meets the threshold but duration is modest versus top-in-class expectations.
Safety is acceptable with routine local irritation signals.
Adoption is gradual and concentrated in specialty clinics.
Pricing is set close to injectables but with limited differentiation in reimbursement negotiations.

Bear case

Efficacy requires higher or more frequent dosing to match injection benchmarks, driving adverse events or COGS concerns.
Local tolerability undermines repeat dosing.
Delays in regulatory review or manufacturing scale-up stretch the timeline.
Competitive entry or strong injectable standard-of-care limits share.

What diligence items matter most for ORABLOC as an asset?

Investors should validate these points before underwriting valuation:

Clinical diligence

Endpoint definition alignment with standard care metrics used by injectables in the same indication.
Dose selection logic tied to both efficacy and safety.
Duration evidence across enough timepoints to support retreatment modeling.

CMC diligence

Stability data that supports shelf life and shipping at scale.
In-process controls and manufacturing consistency tied to delivery reliability.

Commercial diligence

Real physician adoption evidence or credible proxy metrics (pilot sites, training plans, workflow integration).
Payer rationale and dossier structure that anticipates comparative skepticism versus injectables.
KOL and guideline positioning prospects tied to measurable outcomes and retreatment intervals.

Key Takeaways

ORABLOC’s investment case is built on demonstrating that an oromucosal botulinum approach delivers durable clinical effect with repeatable dosing and manageable local safety.
The competitive benchmark is not simply “another botulinum toxin,” it is injection-based standard care with established evidence and payer pathways.
Revenue upside depends on retreatment interval, tolerability over multiple cycles, and the speed of formulary acceptance for a non-injectable route.
The thesis breaks most often on efficacy-duration gaps, repeat-dose tolerability, or route-specific CMC/regulatory friction that delays approval or increases unit economics stress.

FAQs

1) What is the primary value driver for ORABLOC?

Demonstrated clinical efficacy and duration that support a stable retreatment interval with repeat-dose tolerability acceptable for routine clinical practice.

2) How does ORABLOC compete against injected botulinum toxins?

On comparable or superior outcomes with less administration burden, backed by strong safety and dosing reproducibility that enables payer coverage and physician adoption.

3) What are the highest-impact clinical risks?

Insufficient duration or onset, local oromucosal adverse events limiting repeat dosing, and any immunogenicity signals that reduce patient response over time.

4) What are the highest-impact commercial risks?

Formulary access delays versus injectables, weak differentiation beyond convenience, and pricing pressure if outcomes do not justify a distinct reimbursement position.

5) How should investors model launch adoption?

Use a workflow-fit adoption curve tied to retreatment frequency, discontinuation rates from local tolerability, and payer acceptance timelines based on the strength of comparative evidence.

Cited Sources

(No sources provided.)

ORABLOC Drug Patent Profile

Which patents cover Orabloc, and when can generic versions of Orabloc launch?

AI Deep Research

Questions you can ask:

Summary for ORABLOC

US Patents and Regulatory Information for ORABLOC

ORABLOC Market Analysis and Financial Projection